Published, peer-reviewed studies show the clinical impact of the Karius Test® in institutions around the country.
Antimicrob Steward Healthc Epidemiol. 2023; 3(1): e31. Published online 2023 Feb 17. doi: 10.1017/ash.2022.356
PMCID: PMC9972541 | PMID: 36865703
The effect of a plasma next-generation sequencing test on antimicrobial management in immunocompetent and immunocompromised patients - A single-center retrospective study
Denise Marie A Francisco 1, Laila Woc-Colburn 2, Travis J Carlson 3, Todd Lasco 4, Miriam Barrett 4, Mayar Al Mohajer 1
1 Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas.
2 Division of Infectious Diseases Emory University School of Medicine, Atlanta, Georgia.
3 Department of Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, North Carolina.
4 Department of Pathology and Clinical Microbiology, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, Texas.
Plasma NGS testing is associated with a change in antimicrobial management in most cases. We observed a decrease in glycopeptide use after NGS results, which highlights physicians’ comfort in withdrawing methicillin-resistant Staphylococcus aureus (MRSA) coverage. In addition, antimycobacterial coverage increased, corresponding with early mycobacterial detection by NGS. Further studies are needed to determine effective ways to use NGS testing as an antimicrobial stewardship tool.
Scientific Publications, Case Studies, and Clinical Trials
Search through multiple publications showing the efficacy of the Karius Test.
View abstracts that evaluated the metagenomic sequencing of the Karius Test.
View clinical trials validating the Karius Test’s ability to detect pathogens in various clinical contexts.